乙型肝炎病毒感染自然史不同分期Tfh细胞相关细胞因子表达特征

肝脏 ›› 2017, Vol. 22 ›› Issue (12): 1129-1132.

乙型肝炎病毒感染自然史不同分期Tfh细胞相关细胞因子表达特征

王燕,王晓波,马燕,庄小芳,郭峰,王晓忠

830000 乌鲁木齐新疆维吾尔自治区中医医院肝病科

收稿日期:2017-02-23 出版日期:2020-06-15 发布日期:2020-06-15
通讯作者: 王晓忠,Email:wxz125@sina.com
基金资助:
新疆维吾尔自治区科学基金项目(2014211C092)

Received:2017-02-23 Online:2020-06-15 Published:2020-06-15

摘要/Abstract

摘要： 目的探讨Tfh细胞相关细胞因子在慢性乙型肝炎患者自然感染史不同分期的表达特征及意义。方法采用ELISA法检测98例慢性乙型肝炎组及86例对照组Tfh细胞相关细胞因子(IL-21、IL-6、PD-1)的水平。结果 (1)慢性乙型肝炎组患者外周血IL-21、IL-6、PD-1含量均高于健康对照组(P<0.01);(2)IL-21含量免疫清除期(261.71±197.73)ng/L高于低复制期(147.34±96.55) ng/L, 差异有统计学意义(P<0.01);低复制期与免疫耐受期IL-6含量分别为(41.69±23.57) ng/L、(27.27±18.02) ng/L,差异有统计学意义(P<0.01);PD-1含量低复制期(122.05±64.19) ng/L、免疫耐受期(121.72±109.16) ng/L分别与免疫清除期(75.14±57.32) ng/L比较,差异均有统计学意义(P<0.05)。结论 Tfh细胞相关细胞因子(IL-21、IL-6、PD-1)可能是参与乙型肝炎免疫应答中肝细胞损伤、炎症和修复的重要因素。因此,关于Tfh细胞相关细胞因子的研究有望为慢性乙型肝炎免疫治疗提供新靶点。

关键词: 慢性乙型肝炎, IL-21, PD-1, IL-6

王燕,王晓波,马燕,庄小芳,郭峰,王晓忠. 乙型肝炎病毒感染自然史不同分期Tfh细胞相关细胞因子表达特征[J]. 肝脏, 2017, 22(12): 1129-1132.

参考文献

[1] Nance JP,Bélanger S,Johnston RJ,et al. Bcl6 middle domain repressor function is required for T follicular helper cell differentiation and utilizes the corepressor MTA3.Proc Natl Acad Sci U S A,2015,112:13324-13329.
[2] 纪龙珊,孙学华,周振华,等. 滤泡辅助性T淋巴细胞及其在肝脏疾病发生发展中的作用.临床肝胆病杂志,2016,32:1230-1234.
[3] Jia Y,Zeng Z,Li Y,et al. Impaired function of CD4+ T follicular helper (Tfh) cells associated with hepatocellular carcinoma progression. PloS one,2015,10:e0117458.
[4] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015更新版).临床肝胆病杂志,2015,31:1941-1960.
[5] Russo FP,Rodríguez-Castro K,Scribano L,et al. Role of antiviral therapy in the natural history of hepatitis B virus-related chronic liver disease.World J Hepatol,2015,7:1097-1104.
[6] Zare A,Rashki A,Ghahari S,et al. The analysis of correlation between IL-12 gene expression and hepatitis B virus in the affected patients.Virus disease,2015,26:196-199.
[7] Feng J,Lu L,Hua C,et al. High frequency of CD4+ CXCR5+ TFH cells in patients with immune-active chronic hepatitis B.PLoS One,2011,6:e21698.
[8] Attridge K,Kenefeck R,Wardzinski L,et al. IL-21 promotes CD4 T cell responses by phosphatidylinositol 3-kinase-dependent upregulation of CD86 on B cells.J Immunol,2014,192:2195-2201.
[9] Li M,Sun X,Zhou Z,et al. Alterations of IFN-u03b3 and IL-4 of peripheral blood T cells in patients with chronic HBV infection.Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi,2016,32:240-244.
[10] 程雪,单永业,罗亚文,等. 辅助性 T 淋巴细胞17及相关细胞因子在急性乙型肝炎患者外周血中的动态变化及意义.中华传染病杂志,2015,33:518-521.
[11] Chalaris A,Schmidt-Arras D,Yamamoto K,et al. Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease.Dig Dis,2012,30:492-499.
[12] 齐育英,林振忠,明德松. IL-6、IL-10、IL-17在慢性乙型病毒性肝炎患者血中水平分析.中国免疫学杂志,2013,29:1177-1180.
[13] Aniszewska A,Chlodzińska N,Bartkowska K,et al. The expression of interleukin-6 and its receptor in various brain regions and their roles in exploratory behavior and stress responses.J Neuroimmunol,2015, 284: 1-9.
[14] Vashishta M,Khan N,Mehto S,et al. Pneumococal Surface Protein A (PspA) Regulates Programmed Death Ligand 1 Expression on Dendritic Cells in a Toll-Like Receptor 2 and Calcium Dependent Manner. PLoS One,2015,10:e0133601.
[15] Zhang Y,Kang S,Shen J,et al. Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) Expression in epithelial-originated cancer: a meta-analysis.Medicine (Baltimore),2015,94:e515.
[16] Zheng P,Zhou Z. Human Cancer Immunotherapy with PD-1/PD-L1 Blockade.Biomark Cancer,2015,7:15-18.
[17] Haymaker C,Wu R,Bernatchez C,et al. PD-1 and BTLA and CD8(+) T-cell “exhaustion” in cancer: “Exercising” an alternative viewpoint.Oncoimmunology, 2012,1:735-738.
[18] Mahoney KM,Atkins MB. Prognostic and predictive markers for the new immunotherapies. Oncology (Williston Park),2014,28:39-48.